Near-Infrared Light Photobiomodulation Treatment for Retinal Vein Occlusion Macular Oedema

Inclusion Criteria:

• Diagnosis macular edema secondary to branch or central vein occlusion (BRVO or CRVO)
• CMT of >300 µm and less than 550 µm;
• Best corrected visual acuity of 6/6 to 6/24 (letters 87 - 53);
• Intraocular pressure < 25 mmHg;
• Written informed consent has been obtained.

Exclusion Criteria:

• Loss of vision due to other causes (e.g. age-related macular degeneration, myopicmacular degeneration, DME);
• Known allergy to agents used in the study e.g. fluorescein;
• Women who are pregnant, nursing, or planning a pregnancy, or who are of childbearingpotential and not using reliable means of contraception;
• Only eye (vision in other eye <6/60);
• Study eye is an amblyopic eye;
• Macular oedema due to other causes;
• Significant diabetic retinopathy;
• An ocular condition that would prevent visual acuity improvement despite resolution ofoedema (such as foveal atrophy or substantial premacular fibrosis;
• Previous treatment with any anti-VEGF therapy or investigational drugs in the studyeye at any time prior to baseline.
• Previous use of intraocular or periocular steroids in study eye at any time prior tobaseline;
• Cataract surgery within the last 3 months;
• Retinal laser treatment within the last 6 months;
• Media opacity including cataract that already precludes adequate macular photographyor cataract that is likely to require surgery within 6 months;
• Intercurrent severe disease such as septicaemia, any condition which would affectfollow-up;
• History of chronic renal failure requiring dialysis or renal transplant;
• Blood pressure >180/120;
• Participant has a condition or is in a situation that in the investigator's opinionmay put the participant at significant risk, may confound the study results, or mayinterfere significantly with the participant's participation in the study